Genepoint Technologies (Genepoint) is partnering with Zohwyl Therapeutics to establish a cryogenic automated biobank that facilitates the long-term preservation of valuable biological samples and supports the development of next-generation therapeutics.
As China's biopharmaceutical sector continues to expand its global footprint, high-quality biological samples and intelligent sample management have become essential infrastructure for research, clinical translation, and commercialization. Through this collaboration, Genepoint is providing its automated cryogenic storage solution to help Zohwyl Therapeutics build a scalable, intelligent biobank designed to safeguard critical biological resources and accelerate scientific innovation.
Zohwyl Therapeutics is recognized for its innovations in 3D-printed hollow microneedle technology and exosome-based therapeutics—two rapidly expanding fields with wide-ranging applications in drug delivery, regenerative medicine, vaccines, and medical aesthetics.
The company is China's first developer and manufacturer of proprietary hollow microneedle technology. It combines advanced microneedle design, micro/nano 3D printing, and photopolymerization to establish an integrated manufacturing platform capable of large-scale production.
In the field of exosome therapeutics, Zohwyl Therapeutics has developed a proprietary high-efficiency exosome protein encapsulation technology that achieves nearly ten times higher loading efficiency than conventional methods, creating new opportunities for protein-based therapeutics. The company has also established an in-house gene editing platform for stem cell engineering, further strengthening its innovation capabilities.
To support its expanding research and development activities, Zohwyl Therapeutics has implemented an automated biological tissue biobank utilizing Genepoint's automated sample storage technology.
The solution maintains a fully automated cryogenic workflow that minimizes temperature fluctuations during sample handling, helping preserve cell viability and sample integrity throughout long-term storage.
Integrated with digital information management, 5G-enabled remote monitoring, and cloud-based data management, the platform provides:
Automated sample storage and retrieval
Continuous environmental monitoring
Intelligent sample tracking and search
End-to-end sample traceability
Enhanced personnel, sample, and data security
The facility has become a vital platform supporting the preservation of biological resources, scientific research, and the development of future products.
As cell and gene therapies, regenerative medicine, and innovative biologics continue to evolve, standardized and intelligent biobanking is becoming an essential component of modern life science infrastructure.
By combining Zohwyl Therapeutics' expertise in advanced therapeutics with Genepoint's intelligent sample management technologies, the partnership aims to establish a benchmark for automated biobanking in China and support the development of globally competitive biopharmaceutical innovations.
Genepoint remains committed to helping research institutions, hospitals, biopharmaceutical companies, and biobanks safeguard valuable biological resources through intelligent automation, enabling scientists to focus on accelerating discoveries that improve human health.
